Jonathan Jackson - 01 Jun 2022 Form 4 Insider Report for Histogen Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 01 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2022, 16:36:42 UTC
Prior SEC filing: 03 Sep 2021
Next SEC filing: 21 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Susan A. Knudson as attorney-in-fact for Jonathan Jackson

Key filing fact

Jonathan Jackson filed Form 4 for Histogen Inc. on 03 Jun 2022.

Key facts

This page summarizes Jonathan Jackson's Form 4 filing for Histogen Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2022, 16:36.

Change

Previous filing in this sequence was filed on 03 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSTO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,000
Change %
Price: $0.000000
Shares after: 1,000
Date: 01 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,000
Exercise price: $3.20
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On June 2, 2022, the Issuer effected a 1-for-20 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 and the exercise price have been adjusted to reflect the Reverse Stock Split.

Footnote F2

This option was issued to the Reporting Person, a non-employee director of the Issuer, for his service as a director of the Issuer.

Footnote F3

The shares subject to this option become fully vested and exercisable on 6/1/2023, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.